Your browser doesn't support javascript.
loading
Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang, Mengqi; Wang, Lulu; Liu, Wan; Wang, Tian; De Sanctis, Francesco; Zhu, Lifang; Zhang, Guizhong; Cheng, Jian; Cao, Qin; Zhou, Jingying; Tagliabue, Aldo; Bronte, Vincenzo; Yan, Dehong; Wan, Xianchun; Yu, Guang.
Afiliação
  • Zhang M; School of Basic Medical Science, Jinzhou Medical University, Jinzhou 121000, China.
  • Wang L; Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
  • Liu W; Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518036, China.
  • Wang T; Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
  • De Sanctis F; Department of Medicine, Immunology Section, University of Verona, Verona, Italy.
  • Zhu L; Department of Medicine, Immunology Section, University of Verona, Verona, Italy.
  • Zhang G; Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
  • Cheng J; School of Life Science and Technology, Jinan University, Guangzhou 510632, China.
  • Cao Q; Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
  • Zhou J; University of Chinese Academy of Sciences, Beijing 100864, China.
  • Tagliabue A; School of Basic Medical Science, Jinzhou Medical University, Jinzhou 121000, China.
  • Bronte V; Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
  • Yan D; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.
  • Wan X; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong.
  • Yu G; Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
J Immunol Res ; 2022: 2253436, 2022.
Article em En | MEDLINE | ID: mdl-35785030
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artemisininas / Células Supressoras Mieloides / Neoplasias Hepáticas / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: J Immunol Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artemisininas / Células Supressoras Mieloides / Neoplasias Hepáticas / Melanoma Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: J Immunol Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China